Last reviewed · How we verify

Effexor — Competitive Intelligence Brief

Effexor (Effexor) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Neuroscience.

marketed 5-hydroxytryptamine receptor 6, 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2C Neuroscience Small molecule Live · refreshed every 30 min

Target snapshot

Effexor (Effexor) — Wyeth is now a wholly owned subsidiary of Pfizer.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Effexor TARGET Effexor Wyeth is now a wholly owned subsidiary of Pfizer marketed 5-hydroxytryptamine receptor 6, 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2C
Effexor venlafaxine Generic (originally Wyeth/Pfizer) marketed SNRI (Serotonin-norepinephrine reuptake inhibitor) 5-hydroxytryptamine receptor 6, 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2C 1993-12-28

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Effexor — Competitive Intelligence Brief. https://druglandscape.com/ci/effexor. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: